The effect of Oxaliplatin combined with Cyclophosphamide (Oxa-Cyt) treatment on tumors relied on TLR4 signaling; Oxa-Cyt treatment led to an increase of TLR4 selectively in DC cells within the tumor stroma and ultimately led to CD8+ T-cell anti-tumor immunity in lung adenocarcinoma mouse models (98). Here, TLR4 is linked to lung adenocarcinoma.